valsartan
Selected indexed studies
- Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. (JACC Heart Fail, 2020) [PMID:33004114]
- Valsartan/hydrochlorothiazide. (Drugs, 1999) [PMID:10353300]
- The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis. (Int Urol Nephrol, 2024) [PMID:37195574]
_Worker-drafted node — pending editorial review._
Connections
valsartan is a side effect of
Sources
- Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. (2020) pubmed
- Valsartan/hydrochlorothiazide. (1999) pubmed
- The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis. (2024) pubmed
- Valsartan. (2015) pubmed
- Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open-Label, Noninferiority Study (PARASOL Study). (2025) pubmed
- Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. (2022) pubmed
- Nebivolol/Valsartan: A Novel Antihypertensive Fixed-Dose Combination Tablet. (2019) pubmed
- Sacubitril/valsartan: beyond natriuretic peptides. (2017) pubmed
- Sacubitril/valsartan-induced liver injury: A case report and literature review. (2023) pubmed
- [Valsartan contamination]. (2019) pubmed